ClinicalTrials.gg
TerminatedNCT03497780Updated Apr 5, 2023

Longitudinal Assessment of Cartilage Injury and Remodeling After Anterior Cruciate Ligament Rupture and Reconstruction:

An observational study in ACL - Anterior Cruciate Ligament Rupture, ACL Injury and Healthy, sponsored by University of Michigan. Terminated at 2 sites in United States. Open to participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-05.

Sponsored by University of Michigan · Observational

Why this study was terminated
Due to staff departure, study is being discontinued per allocation of resources.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
13
Ages
18 Years to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 11 studies in Anterior Cruciate Ligament Injuries by University of Michigan — 1 open to participants now, 1 under way, none of them phase 3. Anterior Cruciate Ligament Injuries · University of Michigan.

Started
2018
with 1 other
Observational
Only one
of the 11
Registered
6th of 11
by date

Among the 11 studies in Anterior Cruciate Ligament Injuries by University of Michigan, this one is one of 2 that started in 2018, is the only observational one, and was the 6th registered.

By phase

11 studies; the count open now beside each. This study's row is marked.

No phase9 · 1 open
Observationalthis study1 · 0 open
Phase 21 · 0 open

By the year they started

First in 2009; this study’s year is marked. 2 started in 2018.

What they test

Size and results

Median enrollment 31 across the 10 interventional studies, 13 across the 1 observational. Of the 10 that completed or were terminated, 4 (40%) have results posted.

Was this useful?
Watch this landscapeDownload CSVWith an account: a weekly mail of what changed among 11 studies in Anterior Cruciate Ligament Injuries by University of Michigan, or all of them as a file.
02

Study summary

The proposed study will establish novel relationships between intra-articular mesenchymal stem cell (MSC) recruitment, synovial inflammation, biomarkers of cartilage degeneration and joint inflammation, clinical patient factors, and downstream alterations in cartilage composition and morphology to provide novel insights into the pathoetiology of post-traumatic osteoarthritis (PTOA) after ACL injury and reconstruction. The study aims to enroll N=38 total patients with primary, isolated rupture to their anterior cruciate ligament (ACL), who have agreed to participate in the study and who will undergo primary surgical reconstruction by an orthopaedic physician at our two sites. Patients will undergo baseline magnetic resonance imaging (MRI), baseline clinical evaluation, and undergo a baseline blood draw. Subsequent imaging and clinical evaluations will be longitudinally performed at several postoperative timepoints up to 12 months postoperatively.

Read the detailed description

Overall Study Design: This is a prospective, longitudinal cohort study of patients undergoing primary ACL reconstruction following ACL rupture. Surgical treatment and treatment timelines do not deviate from the national and international standards of care. Enrolled patients for study participation will undergo assessments involving blood, urine, and synovial fluid collection, clinical evaluation involving questionnaires and joint laxity testing, and MRI analysis.

Patient Selection and Enrollment: The participating physicians at each site will identify potential subjects from their clinics' patients according to the inclusion/exclusion criteria listed below. Based on surgical volumes at both sites, patients generally undergo ACL reconstruction 8-12 weeks after initial screening. In the preoperative timeframe, all patients will undergo standard physical therapy to address pain, swelling, and motion deficits, as is standard of care at both institutions. Arthroscopic ACL reconstruction will be performed by Dr. Bedi at the University of Michigan, by Professor Ao at Peking University, and by 5 additional surgeons at Peking University. All surgeons will utilize a standardized single-bundle technique with a hamstring or bone-patellar tendon-bone autograft.

03

Conditions studied

  • ACL - Anterior Cruciate Ligament Rupture
  • ACL Injury
  • Healthy

Keywords

  • Healthy Volunteers
  • ACL (Anterior Cruciate Ligament) tear
04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Community sample

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Isolated, traumatic primary anterior cruciate ligament rupture requiring surgical reconstruction
  • Surgical reconstruction performed using a single-bundle technique utilizing an autograft
  • No history of ipsilateral traumatic knee injury or fracture
  • No evidence of Posterior Cruciate Ligament injury or more than grade 1 injury to the Medial or Lateral Collateral Ligament

Exclusion criteria

Exclusion Criteria:

  • \< 18.5 or >35 - Injury occurred longer than 4 weeks before enrollment
  • Intra-articular injection within 3 months of injury
  • Chondral defects greater than 3 cm2 or Outerbridge grade II or higher lesions
  • Pregnant women as they are not eligible for surgery
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
13 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • ACL Tear

    Patients with ACL tears

    Procedure: Anterior cruciate ligament reconstruction

  • Healthy Subjects

    Healthy subjects

Interventions

  • ProcedureAnterior cruciate ligament reconstruction

    Primary surgical reconstruction of the rupture anterior cruciate ligament

06

What researchers measure

Primary outcomes

  1. Change in Articular cartilage surface roughness

    One-year change in articular cartilage surface roughness based on quantitative morphological assessment with 3D MRI.

    Time frame: Baseline (preop), 12 months

  2. Change in Serum Cartilage Oligomeric Matrix Protein (COMP) concentration

    One-year change in the serum concentration of COMP, a biomarker of articular cartilage degeneration.

    Time frame: Baseline (preop), 12 months

  3. Change in International Knee Documentation Committee (IKDC) score

    One year change in IKDC, a patient-reported outcome measure specific to knee injuries.

    Time frame: Baseline (preop), 12 months

Secondary outcomes

  1. Change in quantitative T2 mapping and T1rho mapping relaxation times from MRI.

    Time frame: Baseline (preop), 12 months

  2. Change in concentration of biomarkers of inflammation and cartilage metabolism.

    Time frame: Baseline (preop), 12 months

  3. Change in patient-reported outcome measures

    Time frame: Baseline (preop), 12 months

  4. Change in knee laxity

    Knee laxity will be measured with KT-2000 testing

    Time frame: Baseline (preop), 12 months

07

Study locations

2 sites
  • University of Michigan
    Ann Arbor, Michigan 48105, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2018 to primary completion in Mar 2021, 28 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2018
First posted
Apr 13, 2018
StartActual
Nov 8, 2018
Primary completionActual
Mar 25, 2021
CompletionActual
Mar 25, 2021
Last update
Apr 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03497780
Collaborators
Peking University Health Science Center
Responsible party
Tristan Maerz (Research Investigator, University of Michigan) — Principal investigator
First posted
Apr 13, 2018
Start date
Nov 8, 2018
Primary completion
Mar 25, 2021
Completion
Mar 25, 2021
Last update
Apr 5, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion